Clinical trials: Liver Tumors
Carcinoma, Hepatocellular, Hepatoma
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC).
- Trial name
- NCT00503867
- Testing
- SIR-Spheres microspheres
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sirtex Medical
Neoplasm Malignant
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Primary Objectives: To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment To determine the pharmacokinetics (PKs) of…
- Trial name
- NCT01140607
- Testing
- Cabazitaxel (XRP6258)
- Where
- 14 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sanofi
Head and Neck Cancers, Breast Cancer
Feasibility Study of CBCT for IGRT in Cancer Patients
Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy…
- Conditions
- Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer
- Trial name
- NCT06681233
- Testing
- Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Varian, a Siemens Healthineers Company
Metastatic Colorectal Cancer
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks…
- Trial name
- EGIA-003 (NCT06225843)
- Testing
- Sotevtamab, FOLFOX
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Alethia Biotherapeutics
Hepatocellular Carcinoma (HCC)
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable…
- Trial name
- NCT07176650
- Testing
- HLX13, Yervoy, OPDIVO
- Where
- 51 sites in United States, China
- Volunteers
- 246 people
- Sponsor
- Shanghai Henlius Biotech
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
The purpose of this study is to investigate on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation
- Trial name
- NCT02210182
- Testing
- Oral Pentamidine
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Oncozyme Pharma Inc.
Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer
- Trial name
- NCT03167775
- Testing
- Elemene Injection/Elemene Oral Emulusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Hepatocellular Carcinoma
A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of a continuous hepatic arterial infusion combination therapy with OPC-18 and 5-FU versus BST in patients with highly advanced hepatocellular carcinoma for which…
- Trial name
- NCT00524498
- Testing
- OPC-18, cisplatin
- Where
- 7 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Gastrointestinal Cancer, Cholangiocarcinoma
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
This study aims to find out: 1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2.
- Conditions
- Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer, Colorectal Adenocarcinoma
- Trial name
- NCT05411133
- Testing
- Cabotamig (ARB202)
- Where
- 3 sites in Australia, Hong Kong
- Volunteers
- 33 people
- Sponsor
- Arbele Pty Ltd
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the…
- Conditions
- Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma
- Trial name
- NCT03232593
- Testing
- Atezolizumab
- Where
- 56 sites in South Korea
- Volunteers
- 1,758 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC)
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07291076
- Testing
- Pumitamig, Ipilimumab
- Where
- 67 sites in United States, Australia and 12 more
- Volunteers
- 198 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate…
- Trial name
- ORION (NCT05605782)
- Where
- United States
- Volunteers
- 9,000 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with hepatocellular carcinoma who have failed prior systemic treatment (chemotherapy).
- Trial name
- ADI-PEG 20 (NCT01287585)
- Testing
- ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol), Best Supportive Care
- Where
- 73 sites in United States, China and 4 more
- Volunteers
- 636 people
- Sponsor
- Polaris Group
Advanced Solid Tumors, Hepatocellular Carcinoma
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC). Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).
- Trial name
- NCT01668017
- Testing
- Pimasertib
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany